Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges
about
Approaches to vaccines against Orientia tsutsugamushiMechanisms of HIV protein degradation into epitopes: implications for vaccine designDiscovery of a protective Rickettsia prowazekii antigen recognized by CD8+ T cells, RP884, using an in vivo screening platformImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesTCR stimulation strength is inversely associated with establishment of functional brain-resident memory CD8 T cells during persistent viral infection.Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239Fragmentation of SIV-gag vaccine induces broader T cell responses.Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c miceImmunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccineEarly Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in MiceIn silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV.Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccineControl of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.Association of lymph-node antigens with lower Gag-specific central-memory and higher Env-specific effector-memory CD8(+) T-cell frequencies in a macaque AIDS modelTransmission of chimeric HIV by mating in conventional mice: prevention by pre-exposure antiretroviral therapy and reduced susceptibility during estrus.Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection.Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.Enhanced human immunodeficiency virus Type 1 expression and neuropathogenesis in knockout mice lacking Type I interferon responses.Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.Multiple T-cell responses are associated with better control of acute HIV-1 infection: An observational study.T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus loadAdvances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.HIV-1 vaccine immunogen design strategies.New challenges in therapeutic vaccines against HIV infection.T cell response specificity and magnitude against SIVmac239 are not concordant in major histocompatibility complex-matched animals.Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes.Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine.Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.Harnessing evolutionary biology to combat infectious disease.T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin.The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment.Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against HIV-1 infection
P2860
Q26849239-EC74B2C9-8E17-40BC-AFE3-4D03B906BE09Q26866505-CC39CD6E-D59F-4E05-B170-346B025F8E90Q27304785-ACA542E1-01B2-4537-8D6B-DB04B2983CE9Q27319783-6519CD2C-0F9E-47AE-84B9-0F032B1164DAQ33605976-1AEDCC3F-3725-4202-94FD-D507365F7520Q33744109-170AB90B-AF70-4D5D-B018-D271DF054336Q34464743-99DC0FB8-E239-4CC6-977B-857B32D5A743Q34592940-F4A0ED43-24FA-4CFA-94B2-E6DC647C030BQ35326248-79854453-4AF5-4038-8BEB-D3617B1560B3Q35641132-F860CAA9-BA79-421C-A7F5-52C29D412A14Q35648017-E4E083C3-0530-4B24-B0DE-B80AA398FFDAQ35813585-CEE2BD0A-AC27-4FC5-8123-844100C05FD6Q35880666-A2E9B91E-54BB-4D09-BA9E-7C9DF1E00E1BQ35887235-218C7AE4-5A9C-4DB7-9144-B730B49D13D5Q36246319-5075C08F-5369-48C6-901B-339A28149468Q36367066-203EC686-C256-4F6B-9A7F-D7CC175BCD20Q36467153-37CB63B0-F887-4D86-B624-D2E21D83ABFDQ36624369-1D1ED2AB-B5AE-42D6-A27A-CD4D68C54B53Q36756865-4D081FF9-2D58-4441-A053-B316C55D65EDQ37121711-8682BDA6-1D5B-4DED-A7F8-9CD884FFB899Q37137806-0DC64A0A-2299-451D-9302-86567700A829Q37156309-AC0D4DFD-A68E-4B91-B094-81AB9EF749ADQ37221660-0E7802DC-E3CA-4A6A-B003-1C553BF30830Q37410928-A5982E98-18B1-46E5-AAE4-92FA3DB6D1E3Q37502368-5B10CD24-9A7E-4BB9-A443-73926F69BEEEQ37605728-87CB65AB-1D40-420C-B7E4-DB0BE964037FQ37693810-FD1C65CB-ECBC-4ECD-83A1-0DD1F7C46D8BQ37997825-47E3D239-CECB-47A4-9E49-C883B1ABDAAAQ38330424-C2A8AFDF-E10E-4B26-981C-B7542F31C32AQ38692205-F83EECDD-1DDC-4852-A81D-E63A7917FFE8Q39326760-E7359339-243A-44A3-95A3-DEC3CC620CDDQ40118193-7B59D6E6-7DEE-4DF0-89E3-6EA4CDAC4BBAQ40207674-80A7E574-9BD4-4556-973E-F33E7DEF23CFQ40866024-AFF7BFF0-FDC3-41CD-9BCD-9E5C87B64B80Q42229225-ABBB5EEF-D7CA-4328-9ED7-3F295FF6FDABQ43090543-0A8ADB47-6E00-4DFA-B9F5-64B20A4F202FQ45325937-19760A43-8994-4D4E-97BD-B58C8C12805FQ47569740-A0779AB9-EBE1-4D1F-926E-09E38AE931E5Q55255033-2E93C64C-0748-4711-9BA4-498E6C2E7F80Q57023723-BE7CAD5C-9424-4A8B-81D5-D0DC2C2B24A4
P2860
Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Protective efficacy of seriall ...... topes against virus challenges
@ast
Protective efficacy of seriall ...... topes against virus challenges
@en
type
label
Protective efficacy of seriall ...... topes against virus challenges
@ast
Protective efficacy of seriall ...... topes against virus challenges
@en
prefLabel
Protective efficacy of seriall ...... topes against virus challenges
@ast
Protective efficacy of seriall ...... topes against virus challenges
@en
P2093
P2860
P1433
P1476
Protective efficacy of seriall ...... topes against virus challenges
@en
P2093
Andrew J McMichael
David J Volsky
Eung-Jun Im
Jessie P Hong
Mary Jane Potash
Peter Liljeström
Sven Létourneau
Tomáš Hanke
Yaowaluck Roshorm
P2860
P304
P356
10.1371/JOURNAL.PPAT.1002041
P577
2011-05-19T00:00:00Z